teaser
Actavis and Bioluz enter a co-development relationship to create ready to administer IV pharmaceuticals
Actavis’ hospitals division has signed a co-development contract with Bioluz, experts in the development and manufacture of injectable drugs (IV drugs) in ready to administer bags.
Demand for ready to use products is increasing primarily as they offer greater security that products are correctly prepared whilst minimising occupational exposure to dangerous products and saving time.
Actavis is one of the leading generic pharmaceutical manufacturers in the world. Actavis has been rapidly expanding its presence in the hospitals market and has a range of injectable products in addition to a comprehensive oncology range comprising over 30 molecules.
Bioluz is a fully integrated drug manufacturer focused on premixed drugs in flexible bags and is part of the Technoflex group – European leader in design and production of infusion bags and connectors. Bioluz is the only European independent CMO to offer aseptic filling of IV drugs in sterile flexible bags.
James Burt, Global Director of Actavis’ Hospital Unit commented: “The contract with Bioluz signifies an important development for our hospitals business, as it enables us to provide further diversity in our product offering and a strong foothold in the fast growing market for IV drugs in ready to use format.”
Jean-Jacques Chappaz, Bioluz CEO commented: “The deal signed with Actavis is in line with our will to partner with the major pharmaceutical companies. There is no doubt about increasing demand in premixed IV drugs, mainly for safety issues.”
